Cocrystal Announces Board Changes
January 07 2019 - 8:30AM
Cocrystal Pharma, Inc., a biotechnology company with a proprietary
technology platform focused on developing medicines to treat viral
diseases, today announced changes to its board of directors. Dr.
Raymond F Schinazi, who has served as chairman or co-chairman of
Cocrystal’s board of directors since November 2014, has elected to
retire from the board on February 1, 2019. Pending compliance
approval from his academic affiliations, he will become a special
advisor to the CEO and also serve on the scientific advisory board.
The board of directors has appointed Dr. Gary
Wilcox to serve as chairman, in addition to his position as CEO,
effective on February 1, 2019. “On behalf of Cocrystal’s management
and Board, I would like to thank Ray for his many contributions
over the last four years,” said Dr. Wilcox. “I am delighted that
Cocrystal will be able to continue to benefit from his expertise as
an advisor.” The company also announced that Dr. David
Block has also elected to retire from the board on
January 4.
The Company is in the process of reviewing
several identified board candidates. The board looks forward to
working with its new members to help propel Cocrystal forward in
its mission.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication machinery of influenza
viruses, hepatitis C viruses, and noroviruses. Cocrystal employs
unique structure-based technologies and Nobel Prize winning
expertise to create first- and best-in-class antiviral drugs. Novel
inhibitors effective against influenza strains A and B have been
identified and are in the preclinical stage. Several of these have
potencies approaching single digit nanomolar. The Company’s lead
candidate CC- 42344 for influenza strain A is effective in animal
models against both the pandemic and seasonal strains of influenza
A. We continue to identify and develop non-nucleoside polymerase
inhibitors for Norovirus infections using the Company’s proprietary
structure-based drug design technology platform. For further
information about Cocrystal, please
visit www.cocrystalpharma.com.
Investor and Media Contact:Jenene Thomas
Communications, LLC (833) 475-8247COCP@jtcir.com
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Sep 2023 to Sep 2024